

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2014261336 B2**

(54) Title
Oral dosing of GLP-1 compounds

(51) International Patent Classification(s)
A61K 38/26 (2006.01)

(21) Application No: **2014261336**

(22) Date of Filing: **2014.05.02**

(87) WIPO No: **WO14/177683**

(30) Priority Data

(31) Number
13166205.8

(32) Date
2013.05.02

(33) Country
EP

(43) Publication Date: **2014.11.06**

(44) Accepted Journal Date: **2019.02.28**

(71) Applicant(s)
Novo Nordisk A/S

(72) Inventor(s)
Nielsen, Flemming Seier;Sauerberg, Per

(74) Agent / Attorney
Shelston IP Pty Ltd., L 9 60 Margaret St, Sydney, NSW, 2000, AU

(56) Related Art
WO 2008033888 A2
US 20130053311 A1
EP 2565202 A1
STEINERT et al., " Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects "Am.J.Clin.Nutr., (2010), Vol.92, pages 810 - 817